In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat

Jane E Sykes, Greg Hodge, Anil Singapuri, Mai Lee Yang, Angela C Gelli, George Richard Thompson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Elevated fluconazole minimum inhibitory concentrations (MICs) are more frequently observed in Cryptococcus gattii compared to C. neoformans isolates; however, the development of in vivo resistance and the molecular mechanisms responsible have not been reported for this species. We report a case of Cryptococcus gattii (molecular type VGIII) that developed reduced susceptibility to fluconazole during therapy and delineate the molecular mechanisms responsible. Multilocus sequence typing and quantitative DNA analysis of the pre- and post-treatment isolates was performed using well-characterized methods. Pre- and post-treatment clinical isolates were confirmed isogenic, and no differences in ERG11 or PDR11 sequences were found. qPCR found an overexpression of ERG11 and the efflux pump PDR11 in the resistant isolate compared to the isolate collected prior to initiation of antifungal therapy. Reversion to wild-type susceptibility was observed when maintained in antifungal-free media confirming the in vivo development of heteroresistance. The in vivo development of heteroresistance to fluconazole in our patient with C. gattii is secondary to overexpression of the efflux pump PDR11 and the drug target ERG11. Additional work in other clinical isolates with elevated fluconazole MICs is warranted to evaluate the frequency of heteroresistance versus point mutations as a cause of resistance.

Original languageEnglish (US)
Pages (from-to)396-401
Number of pages6
JournalMedical Mycology
Volume55
Issue number4
DOIs
StatePublished - Jun 1 2017

Fingerprint

Cryptococcus gattii
Fluconazole
Cats
Microbial Sensitivity Tests
Therapeutics
Multilocus Sequence Typing
Point Mutation
DNA

Keywords

  • Cryptococcus gattii
  • fluconazole
  • heteroresistance
  • in vivo
  • resistance
  • triazole
  • VGIII

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat. / Sykes, Jane E; Hodge, Greg; Singapuri, Anil; Yang, Mai Lee; Gelli, Angela C; Thompson, George Richard.

In: Medical Mycology, Vol. 55, No. 4, 01.06.2017, p. 396-401.

Research output: Contribution to journalArticle

@article{3e5514b340b74cbaba17fe0f45c97954,
title = "In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat",
abstract = "Elevated fluconazole minimum inhibitory concentrations (MICs) are more frequently observed in Cryptococcus gattii compared to C. neoformans isolates; however, the development of in vivo resistance and the molecular mechanisms responsible have not been reported for this species. We report a case of Cryptococcus gattii (molecular type VGIII) that developed reduced susceptibility to fluconazole during therapy and delineate the molecular mechanisms responsible. Multilocus sequence typing and quantitative DNA analysis of the pre- and post-treatment isolates was performed using well-characterized methods. Pre- and post-treatment clinical isolates were confirmed isogenic, and no differences in ERG11 or PDR11 sequences were found. qPCR found an overexpression of ERG11 and the efflux pump PDR11 in the resistant isolate compared to the isolate collected prior to initiation of antifungal therapy. Reversion to wild-type susceptibility was observed when maintained in antifungal-free media confirming the in vivo development of heteroresistance. The in vivo development of heteroresistance to fluconazole in our patient with C. gattii is secondary to overexpression of the efflux pump PDR11 and the drug target ERG11. Additional work in other clinical isolates with elevated fluconazole MICs is warranted to evaluate the frequency of heteroresistance versus point mutations as a cause of resistance.",
keywords = "Cryptococcus gattii, fluconazole, heteroresistance, in vivo, resistance, triazole, VGIII",
author = "Sykes, {Jane E} and Greg Hodge and Anil Singapuri and Yang, {Mai Lee} and Gelli, {Angela C} and Thompson, {George Richard}",
year = "2017",
month = "6",
day = "1",
doi = "10.1093/mmy/myw104",
language = "English (US)",
volume = "55",
pages = "396--401",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat

AU - Sykes, Jane E

AU - Hodge, Greg

AU - Singapuri, Anil

AU - Yang, Mai Lee

AU - Gelli, Angela C

AU - Thompson, George Richard

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Elevated fluconazole minimum inhibitory concentrations (MICs) are more frequently observed in Cryptococcus gattii compared to C. neoformans isolates; however, the development of in vivo resistance and the molecular mechanisms responsible have not been reported for this species. We report a case of Cryptococcus gattii (molecular type VGIII) that developed reduced susceptibility to fluconazole during therapy and delineate the molecular mechanisms responsible. Multilocus sequence typing and quantitative DNA analysis of the pre- and post-treatment isolates was performed using well-characterized methods. Pre- and post-treatment clinical isolates were confirmed isogenic, and no differences in ERG11 or PDR11 sequences were found. qPCR found an overexpression of ERG11 and the efflux pump PDR11 in the resistant isolate compared to the isolate collected prior to initiation of antifungal therapy. Reversion to wild-type susceptibility was observed when maintained in antifungal-free media confirming the in vivo development of heteroresistance. The in vivo development of heteroresistance to fluconazole in our patient with C. gattii is secondary to overexpression of the efflux pump PDR11 and the drug target ERG11. Additional work in other clinical isolates with elevated fluconazole MICs is warranted to evaluate the frequency of heteroresistance versus point mutations as a cause of resistance.

AB - Elevated fluconazole minimum inhibitory concentrations (MICs) are more frequently observed in Cryptococcus gattii compared to C. neoformans isolates; however, the development of in vivo resistance and the molecular mechanisms responsible have not been reported for this species. We report a case of Cryptococcus gattii (molecular type VGIII) that developed reduced susceptibility to fluconazole during therapy and delineate the molecular mechanisms responsible. Multilocus sequence typing and quantitative DNA analysis of the pre- and post-treatment isolates was performed using well-characterized methods. Pre- and post-treatment clinical isolates were confirmed isogenic, and no differences in ERG11 or PDR11 sequences were found. qPCR found an overexpression of ERG11 and the efflux pump PDR11 in the resistant isolate compared to the isolate collected prior to initiation of antifungal therapy. Reversion to wild-type susceptibility was observed when maintained in antifungal-free media confirming the in vivo development of heteroresistance. The in vivo development of heteroresistance to fluconazole in our patient with C. gattii is secondary to overexpression of the efflux pump PDR11 and the drug target ERG11. Additional work in other clinical isolates with elevated fluconazole MICs is warranted to evaluate the frequency of heteroresistance versus point mutations as a cause of resistance.

KW - Cryptococcus gattii

KW - fluconazole

KW - heteroresistance

KW - in vivo

KW - resistance

KW - triazole

KW - VGIII

UR - http://www.scopus.com/inward/record.url?scp=85039789618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039789618&partnerID=8YFLogxK

U2 - 10.1093/mmy/myw104

DO - 10.1093/mmy/myw104

M3 - Article

VL - 55

SP - 396

EP - 401

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 4

ER -